- MindBio Therapeutics (CSE:MBIO) received the first batch of its drug for take-home use in Phase 2 psychedelic microdosing clinical trials
- The psychedelic stock’s drug, MB22001, is a proprietary titratable form of Lysergic Acid Diethylamide (LSD) for safe take home microdosing in patients suffering from major depressive disorder
- This marks the first take-home approvals for psychedelic microdosing in the world
- MindBio Therapeutics Corp. (CSE:MBIO) opened trading at $0.03 per share
MindBio Therapeutics (CSE:MBIO) received the first batch of its drug for take-home use in Phase 2 psychedelic microdosing clinical trials.
The psychedelic stock’s drug, MB22001, is a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for safe take-home microdosing in patients suffering from major depressive disorder. MB22001 has been manufactured ready for use in Phase 2 clinical trials.
The team has received approval from the “ethics committee” and “clinical trials registry,” although MindBio Therapeutics did not state in what country or jursidiction those bodies are based. Dosing in the first cohort of clinical trial participants is expected to begin shortly after final ministerial approvals are received. This marks the first take-home approvals for psychedelic microdosing in the world.
The Vancouver-based company’s LSD-microdosing randomized controlled clinical trials have yielded positive top-line data to date, such as improved quality of sleep including REM and total time of sleep and statistically significant enhancements in subjective feelings of “happiness,” “social connectivity” and “energy.” The target is commercialization of microdosing treatments with a package of proprietary solutions for safe and effective at-home use of psychedelics.
The company has two fully funded Phase 2 LSD-microdosing clinical trials starting shortly. The first trial focuses on major depressive disorder, where 20 patients meeting certain criteria will receive an open label eight-week LSD microdosing treatment regimen in an at-home setting.
MindBio Chief Executive Officer Justin Hanka said in a news release that, assuming the team starts dosing patients before September, they should have top-line results data to share with the market later in the year.
MindBio is a biotech and biopharma company focused on creating treatments for mental health conditions. It is the first psychedelics stock in history to have clinical trials approved for LSD take-home use.
MindBio Therapeutics Corp. (CSE:MBIO) opened trading at $0.03 per share.
Join the discussion: Find out what everybody’s saying about this stock on the MindBio Therapeutics Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.